To find more information on UCLH CRF Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
GO42144A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination with either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients with Advanced Malignancies | |
---|---|
Local Project Reference: | 140092 |
Principal Investigator: | Dr. Martin Forster |
Drug Class/ Treatment: | AZD7648 (KRAS G12C Inhibitor) Monotherapy and Combination with Anti-Cancer Therapies |
Patient Population: | Advanced or Metastatic Solid Tumours with KRAS G12c Mutation |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
IMC-F106C-101A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers | |
---|---|
Local Project Reference: | 130728 |
Principal Investigator: | Dr. Heather Shaw |
Drug Class/ Treatment: | IMC-F106C (Bispecific Antibody against HLA-A*02:01) |
Patient Population: | HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
GARNETA Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors. | |
---|---|
Local Project Reference: | 16/0355 |
Principal Investigator: | Dr. Rowan Miller |
Drug Class/ Treatment: | TSR-042 (Dorstarlimab) (Anti PD-L1 Monoclonal Antibody) |
Patient Population: | Advanced Solid Tumours Cohort F - Patients with Recurrent or Advanced Non-endometrial and non-GI dMMR/MSI-H Solid Tumours or POLE-Mut Cancers |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
NX-1607-101A Phase 1a Dose Escalation Safety and Tolerability Study of NX-1607 a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor in Adults with Advanced Malignancies with Phase 1b Expansion in Select Tumor Types: A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types | |
---|---|
Local Project Reference: | 140364 |
Principal Investigator: | Prof. Daniel Hochhauser |
Drug Class/ Treatment: | NX-1607 - CBL-B Inhibitor |
Patient Population: | Advanced Malignancies |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
TAPISTRY (BO41932)TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL | |
---|---|
Local Project Reference: | 138000 |
Principal Investigator: | Dr. Martin Forster |
Drug Class/ Treatment: |
|
Patient Population: | Solid Tumours:
|
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
MODI-1-001Modi-1 in Patients with Breast, Head & Neck, Ovarian or Renal Cancer: A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer | |
---|---|
Local Project Reference: | 142749 |
Principal Investigator: | Dr. Rowan Miller |
Drug Class/ Treatment: | Modi-1 - Novel Cancer Vaccine |
Patient Population: | Advanced Solid Tumours:
|
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
Immunophotonics ZZA55720Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients | |
---|---|
Local Project Reference: | 148701 |
Principal Investigator: | Dr Steve Bandula |
Drug Class/Treatment: | IP-001 (inCVAX - cancer vaccine) Intratumoral Injection folllowing Thermal Ablation |
Patient Population: | Advanced Solid Tumours
|
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
PARPA-293-001Dose Escalation Study of NMS-03305293 in Patients with Selected Advanced/Metastatic Solid Tumours: A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors | |
---|---|
Local Project Reference: | 155266 |
Principal Investigator: | Dr Michael Flynn |
Drug Class/Treatment: | NMS-03305293 (PARP Inhibitor) Dose Expansion Cohorts |
Patient Population: | Advanced Solid Tumours: Schedule B Arm - Dose Expansion
|
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
TAK-676-1002An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors | |||
---|---|---|---|
Local Project Reference: | 153491 | ||
Principal Investigator: | Dr Martin Forster | ||
Drug Class/ Treatment: | TAK-676 (Novel Stimulator of Interferon Genes (STING) Single Agent and in Combination with Pembrolizumab | ||
Patient Population: | Advanced Solid Tumours:
| ||
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
EP0031-101A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies | |
---|---|
Local Project Reference: | 151414 |
Principal Investigator: | Dr Martin Forster |
Drug Class/ Treatment: | EP0031-101 (Selective RET Inhibitor) |
Patient Population: | Advanced RET-Altered Malignancies
|
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
Mobilize (mRNA-4359-P101)Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors | |
---|---|
Local Project Reference: | 158203 |
Principal Investigator: | Dr Martin Forster |
Drug Class/ Treatment: | mRNA-4359-P101 (Checkpoint mRNA cancer vaccine) Combination with Checkpoint Inhibitors:
|
Patient Population: | Advanced Solid Tumours:
|
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
NVG111-101NVG111-101: An open-label, phase 1/2, first in human study investigating the safety, tolerability, pharmacokinetics and efficacy of NVG-111 in subjects with relapsed/refractory chronic lymphocytic leukaemia and mantle cell lymphoma. | |
---|---|
Local Project Reference: | 135715 |
Principal Investigator: | Dr William Townsend |
Drug Class/ Treatment: | NVG-111 (Receptor Tyrosine Kinase Like Orphan Like Receptor 1 (ROR1) Bispecific Antibody) |
Patient Population: |
|
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
GCT1047-01First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors | |
---|---|
Local Project Reference: | 157969 |
Principal Investigator: | Dr Michael Flynn |
Drug Class/ Treatment: | GEN1047 (DuoBody®-CD3×B7H4 Bispecific Antibody) |
Patient Population: | Advanced Solid Tumours:
|
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
Mobilize (mRNA-4359-P101)Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors | |
---|---|
Local Project Reference: | 158203 |
Principal Investigator: | Dr Martin Forster |
Drug Class/ Treatment: | mRNA-4349 + Pembrolizumab Dose Confirmation |
Patient Population: | Arm 1 B:
|
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
GTAEXS617-001A Phase 1/2 open-label multicenter study to assess the safety, pharmacokinetics, and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors | |
---|---|
Local Project Reference: | 155196 |
Principal Investigator: | Dr Martin Forster |
Drug Class/ Treatment: | GTAEXS617 (Selective CDK7 Inhibitor) Dose Escalation |
Patient Population: | Advanced Solid Tumours |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
XB002-101 (JEWEL-101)A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | |
---|---|
Local Project Reference: | 153449 |
Principal Investigator: | Dr Michael Flynn |
Drug Class/ Treatment: | XB002 (Tissue factor (TF)–targeted antibody-drug conjugate) |
Patient Population: | Advanced Solid Tumours |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
ROLoROLo: Phase II study of ROS1 targeting with crizotinib in advanced E-cadherin negative, ER positive lobular breast cancer or diffuse gastric cancer | |
---|---|
Local Project Reference: | 18/0518 |
Principal Investigator: | Dr. Rebecca Roylance |
Drug Class/ Treatment: | Crizotinib (ROS1 Inhibitor) + Fulvestrant (Hormone Injections) |
Patient Population: |
|
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
DETERMINEAn Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers with Actionable Genomic Alterations, including Common Cancers with Rare Actionable Alterations | |||
---|---|---|---|
Local Project Reference: | 150307 | ||
Principal Investigator: | Dr Martin Forster | ||
Drug Class/ Treatment: |
| ||
Patient Population: | Adult, Paediatric and Teenage/Young Adult (TYA) Cancers with Actionable Genomic Alterations:
| ||
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
OVM-200-100 First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine: A Phase 1, Multicenter, Open-label, Nonrandomized, First-in-human Study of OVM-200 as a Therapeutic Vaccine in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer, Ovarian Cancer, and Prostate Cancer | |
---|---|
Local Project Reference: | 138608 |
Principal Investigator: | Dr. Martin Forster |
Drug Class/ Treatment: | OVM-200 (Cancer Vaccine) |
Patient Population: | Locally Advanced or Metastatic: Non-Small Cell Lung Cancer |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |